Aliases & Classifications for Physical Disorder

MalaCards integrated aliases for Physical Disorder:

Name: Physical Disorder 12 15
Physical Illness 71

Classifications:



External Ids:

Disease Ontology 12 DOID:0080015
UMLS 71 C0683323

Summaries for Physical Disorder

Disease Ontology : 12 A disease that has material basis in a genetic abnormality, error with embryonic development, infection or compromised intrauterine environment.

MalaCards based summary : Physical Disorder, also known as physical illness, is related to fetal alcohol spectrum disorder and syngnathia, and has symptoms including illness (finding) An important gene associated with Physical Disorder is ERCC6 (ERCC Excision Repair 6, Chromatin Remodeling Factor), and among its related pathways/superpathways are Dopaminergic Neurogenesis and Tgif disruption of Shh signaling. The drugs Metformin and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and heart, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 74 A physical disorder (as a medical term) is often used as a term in contrast to a mental disorder, in an... more...

Related Diseases for Physical Disorder

Diseases related to Physical Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 202)
# Related Disease Score Top Affiliating Genes
1 fetal alcohol spectrum disorder 32.3 SHH MIR9-1 MIR140 H2AC18
2 syngnathia 32.3 MSX1 IRF6 FGF8
3 orofacial cleft 32.2 TMEM54 SHH PRODH NHLH1 MTHFR MSX1
4 disease of mental health 30.5 RNU4ATAC PRODH MIR9-1 MIR140 H2AC18 ERCC6
5 cerebellar disease 10.8 RNU4ATAC PRODH PAFAH1B1 H2AC18 ERCC6
6 eye degenerative disease 10.8 RNU4ATAC PRODH H2AC18 ERCC6 EPRS1
7 x-linked monogenic disease 10.8 PRODH MIR9-1 H2AC18 ERCC6 EPRS1
8 tooth size 10.8 SHH MSX1 FGF8
9 cerebral degeneration 10.8 SHH PRODH H2AC18 ERCC6 EPRS1 B3GNT2
10 chromosomal disease 10.8 PRODH MIR9-1 MIR140 H2AC18 EPRS1
11 hypomyelinating leukodystrophy 10.8 PRODH H2AC18 ERCC6 EPRS1
12 muscle tissue disease 10.8 RNU4ATAC PRODH MIR9-1 H2AC18 ERCC6 EPRS1
13 spinal disease 10.8 RNU4ATAC PRODH MIR9-1 MIR140 H2AC18
14 endocrine system disease 10.8 RNU4ATAC PRODH MIR9-1 MIR140 H2AC18 EPRS1
15 nervous system disease 10.8 RNU4ATAC PRODH MIR9-1 MIR140 H2AC18 ERCC6
16 immune system disease 10.8 PRODH MIR9-1 MIR140 H2AC18 ERCC6 EPRS1
17 inherited metabolic disorder 10.8 PRODH MTHFR MIR9-1 H2AC18 ERCC6 EPRS1
18 epilepsy, familial temporal lobe, 1 10.8 H2AC18 ERCC6 EPRS1
19 autosomal recessive disease 10.8 RNU4ATAC PRODH MIR9-1 H2AC18 ERCC6 EPRS1
20 x-linked recessive disease 10.8 PRODH H2AC18 ERCC6 EPRS1
21 microcephalic osteodysplastic primordial dwarfism, type ii 10.8 RNU4ATAC MCPH1 CDK5RAP2 ASPM
22 respiratory system disease 10.8 PRODH MIR9-1 MIR140 H2AC18 ERCC6 EPRS1
23 amino acid metabolic disorder 10.8 PRODH MTHFR H2AC18 EPRS1
24 lissencephaly 2 10.8 WDR62 RNU4ATAC PAFAH1B1
25 heart septal defect 10.8 RNU4ATAC PRODH H2AC18 FGF8
26 central nervous system disease 10.8 PRODH MIR9-1 MIR140 H2AC18 ERCC6 EPRS1
27 glucose metabolism disease 10.8 PRODH MIR9-1 MIR140 H2AC18 EPRS1
28 integumentary system disease 10.8 PRODH MIR9-1 MIR140 H2AC18 ERCC6 EPRS1
29 robinow syndrome, autosomal recessive 1 10.8 H2AC18 ERCC6 EPRS1
30 acquired metabolic disease 10.8 PRODH MIR9-1 MIR140 H2AC18 EPRS1
31 robinow syndrome 10.8 H2AC18 ERCC6 EPRS1
32 pervasive developmental disorder 10.8 PRODH PAFAH1B1 MIR9-1 MIR140 H2AC18 ERCC6
33 colonic disease 10.8 PRODH MIR9-1 MIR140 H2AC18 ERCC6
34 pancreas disease 10.8 PRODH MIR9-1 MIR140 H2AC18 EPRS1
35 intestinal disease 10.8 PRODH MIR9-1 MIR140 H2AC18 ERCC6
36 contractures, pterygia, and spondylocarpotarsal fusion syndrome 1a 10.8 SHH RNU4ATAC PRODH MIR9-1 MIR140 H2AC18
37 peripheral nervous system disease 10.8 RNU4ATAC PRODH H2AC18 ERCC6 EPRS1
38 bone development disease 10.8 SHH RNU4ATAC H2AC18 FGF8
39 urinary system disease 10.8 PRODH MIR9-1 MIR140 H2AC18 ERCC6
40 muscular disease 10.8 RNU4ATAC PRODH MIR9-1 MIR140 H2AC18 ERCC6
41 cleft lip and alveolus 10.8 MSX1 IRF6
42 specific developmental disorder 10.8 RNU4ATAC PRODH MIR9-1 MIR140 H2AC18 ERCC6
43 fetal alcohol syndrome 10.8 SHH MIR9-1 H2AC18
44 connective tissue disease 10.8 RNU4ATAC PRODH MIR9-1 MIR140 H2AC18 ERCC6
45 autosomal genetic disease 10.8 RNU4ATAC PRODH MIR9-1 MIR140 H2AC18 ERCC6
46 microcephaly 8, primary, autosomal recessive 10.8 WDR62 MCPH1 CDK5RAP2
47 microcephaly 6, primary, autosomal recessive 10.8 WDR62 MCPH1 CDK5RAP2 ASPM
48 microcephaly 17, primary, autosomal recessive 10.8 WDR62 MCPH1 CDK5RAP2 ASPM
49 microcephaly 7, primary, autosomal recessive 10.8 WDR62 MCPH1 CDK5RAP2 ASPM
50 microcephaly 3, primary, autosomal recessive 10.8 WDR62 MCPH1 CDK5RAP2 ASPM

Graphical network of the top 20 diseases related to Physical Disorder:



Diseases related to Physical Disorder

Symptoms & Phenotypes for Physical Disorder

UMLS symptoms related to Physical Disorder:


illness (finding)

GenomeRNAi Phenotypes related to Physical Disorder according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.55 IRF6
2 Increased shRNA abundance (Z-score > 2) GR00366-A-128 9.55 FGF8
3 Increased shRNA abundance (Z-score > 2) GR00366-A-139 9.55 FGF8
4 Increased shRNA abundance (Z-score > 2) GR00366-A-140 9.55 FGF8
5 Increased shRNA abundance (Z-score > 2) GR00366-A-155 9.55 B3GNT2 IRF6
6 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.55 IRF6
7 Increased shRNA abundance (Z-score > 2) GR00366-A-180 9.55 FGF8
8 Increased shRNA abundance (Z-score > 2) GR00366-A-205 9.55 FGF8
9 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.55 FGF8
10 Increased shRNA abundance (Z-score > 2) GR00366-A-40 9.55 IRF6
11 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.55 IRF6
12 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.55 FGF8
13 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.55 IRF6
14 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.55 FGF8
15 Increased shRNA abundance (Z-score > 2) GR00366-A-72 9.55 B3GNT2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.55 FGF8

MGI Mouse Phenotypes related to Physical Disorder:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.21 ASPM B3GNT2 CDK5RAP2 EPRS1 ERCC6 FGF8
2 cellular MP:0005384 10.14 ASPM B3GNT2 CDK5RAP2 EPRS1 ERCC6 FGF8
3 integument MP:0010771 9.91 CDK5RAP2 EPRS1 ERCC6 IRF6 MCPH1 MSX1
4 hearing/vestibular/ear MP:0005377 9.87 ASPM ERCC6 FGF8 IRF6 MCPH1 MSX1
5 nervous system MP:0003631 9.77 ASPM B3GNT2 CDK5RAP2 ERCC6 FGF8 MCPH1
6 limbs/digits/tail MP:0005371 9.76 EPRS1 ERCC6 FGF8 IRF6 MSX1 MTHFR
7 skeleton MP:0005390 9.32 CDK5RAP2 EPRS1 ERCC6 FGF8 IRF6 MCPH1

Drugs & Therapeutics for Physical Disorder

Drugs for Physical Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 81)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4 657-24-9 14219 4091
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
4
Ethanol Approved Phase 4 64-17-5 702
5
Flurazepam Approved, Illicit, Investigational Phase 4 17617-23-1 3393
6
Estazolam Approved, Illicit Phase 4 29975-16-4 3261
7
Nitrazepam Approved Phase 4 146-22-5 4506
8
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
9
Trazodone Approved, Investigational Phase 4 19794-93-5 5533
10
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
11
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
12
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
13
Chlorpromazine Approved, Investigational, Vet_approved Phase 4 50-53-3 2726
14
Lithium carbonate Approved Phase 4 554-13-2
15
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
16
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
17
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
18 Antipsychotic Agents Phase 4
19 Neurotransmitter Agents Phase 4
20 Antidepressive Agents Phase 4
21 Psychotropic Drugs Phase 4
22 Serotonin Uptake Inhibitors Phase 4
23 Dopamine Agents Phase 4
24 Dopamine agonists Phase 4
25 Cytochrome P-450 Enzyme Inhibitors Phase 4
26 Quetiapine Fumarate Phase 4 111974-72-2
27 Micronutrients Phase 4
28 Vitamins Phase 4
29 Trace Elements Phase 4
30 Vitamin B 6 Phase 4
31 Vitamin B Complex Phase 4
32 Nicotinic Acids Phase 4
33 Vitamin B3 Phase 4
34 Vasodilator Agents Phase 4
35 Folate Phase 4
36 Nutrients Phase 4
37 Lipid Regulating Agents Phase 4
38 Hypolipidemic Agents Phase 4
39 Antimetabolites Phase 4
40 Vitamin B9 Phase 4
41 Gastrointestinal Agents Phase 4
42 Dopamine Antagonists Phase 4
43 Antiemetics Phase 4
44
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
45
Pyridoxal Experimental, Nutraceutical Phase 4 66-72-8 1050
46
Citalopram Approved Phase 3 59729-33-8 2771
47
tannic acid Approved Phase 3 1401-55-4
48
Eszopiclone Approved, Investigational Phase 3 138729-47-2 969472
49
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
50
Methadone Approved Phase 3 76-99-3 4095

Interventional clinical trials:

(show top 50) (show all 71)
# Name Status NCT ID Phase Drugs
1 Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (METS) - Pilot Study Completed NCT00816907 Phase 4 Metformin;Placebo
2 Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease: A Novel Adjunctive Therapy for Chronic Inflammatory Illness Completed NCT02162862 Phase 4 bupropion-SR
3 12 Week Prospective Double Blind Placebo Controlled Randomized Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety Completed NCT00352469 Phase 4 Seroquel XR
4 Effects of Discontinuation of Benzodiazepine-derivative Hypnotics on Cognitive and Motor Functions in Elderly Persons: a Pilot Study Completed NCT00707915 Phase 4 Drug: Benzodiazepine (listed out below)
5 The Treatment of Acute Schizophrenia With High Dose Niacinmide Plus Ascorbate Plus Pyridoxine Plus Centrum Forte vs. Centrum Forte Only as an Add-On to Risperidone and Dietary Counseling Completed NCT00140166 Phase 4 niacinamide;pyridoxine;ascorbate
6 Comparison of Combination Olanzapine and Lithium and Combination Chlorpromazine and Lithium in the Treatment of a First Manic Episode With Psychotic Features. Completed NCT00202293 Phase 4 Olanzapine;Lithium;Chlorpromazine
7 A Phase III Study of SEP-190 (Eszopiclone) in Patients With Insomnia Completed NCT00770692 Phase 3 Eszopiclone 1 mg- Elderly;Eszopiclone 2 mg- Elderly;Eszopiclone 3 mg- Non-elderly;Eszopiclone 2 mg- Non-elderly
8 The Effect of Fish Oil in Major Depressive Disorder: a Double-blind Placebo-controlled Monotherapy Trail to Demonstrate the Therapeutic Effects of Depression Completed NCT01371383 Phase 2, Phase 3
9 Phase III Open Study of High Dose Escitalopram for the Treatment of Obsessive-Compulsive Disorder in Adults Completed NCT00305500 Phase 3 escitalopram
10 Valnoctamide as a Valproate Substitute With Low Teratogenic Potential: Double-Blind Controlled Clinical Trial Completed NCT00140179 Phase 3 valnoctamide
11 Phase III Study of Maintenance Treatment for Opiate Dependence With Heroin (Diamorphine) Compared to Methadone Completed NCT00268814 Phase 3 Diacetylmorphine;Methadone
12 Electroacupuncture for Major Depression: A Pilot Study Completed NCT00071110 Phase 2
13 Cardiovascular System in Obesity: Effect of Treatment Completed NCT00000506 Phase 2 fenfluramine;phentermine
14 Vagal Nerve Stimulation to Probe Inflammation and Brain in Post-traumatic Stress Recruiting NCT03858985 Phase 1, Phase 2
15 Establishment of Cessation Therapy by Clinical Trials for Subjects With Betel-quid Dependence and Oral Pre-cancer Terminated NCT03010761 Phase 2 escitalopram;Moclobemide;Placebo - Cap
16 Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) For Newly Diagnosed Thyroid Cancer Patients: Randomized Controlled Trial Withdrawn NCT01994200 Phase 1, Phase 2
17 A Pilot Investigational Study: Treatment of Anxiety With Non-Needle Electro-Acupuncture Completed NCT00335946 Phase 1
18 A Bioequivalence Study of Different Formulations of SEP-190 and Food Effect Study in Japanese Healthy Adult Males Completed NCT01055834 Phase 1 Eszopiclone 3 mg;Eszopiclone 1 mg
19 Examining the Efficacy of Acceptance and Commitment Therapy (ACT) Microinterventions for Distressed First-Generation College Students Active, not recruiting NCT04081662 Phase 1
20 Impact of Hospital Admission on Patients With Dementia Unknown status NCT02483065
21 Treatment of Marijuana Withdrawal Syndrome Using Escitalopram and Cognitive-Behavior Therapy- a Double-Blind Placebo-Controlled Study Unknown status NCT00598052 Escitalopram
22 Physical Health of Residents in Psychiatric Institutions Unknown status NCT00969384
23 Investigating Neuroimaging Endophenotypes for Autism Spectrum Disorder Unknown status NCT02720588
24 A Randomized Controlled Trial Evaluation of Brief, Telephone Supported CBT Self-help in Primary Care Patients With Mild to Moderate Depression Unknown status NCT01324648
25 Safety and Efficacy of Escitalopram in the Treatment of Premature Ejaculation A Double-Blind, Placebo-Controlled, Fixed-Dose,Randomized Controlled Study Unknown status NCT00656552 Early Phase 1 Escitalopram
26 Changes in Methylation Status of BDNF Gene After Receiving Dialectical Behavior Therapy in Patients With Borderline Personality Disorder Unknown status NCT02134223
27 Treatment of Depressed Adolescents With Physical Illness Completed NCT00446238
28 Understanding and Treating Neuropsychiatric Symptoms of Pediatric Physical Illness Completed NCT00769353
29 Reducing Depressive Symptoms in Physically Ill Youth Completed NCT00534911
30 Improving Health and Reducing Disability of Depressed Elderly With Chronic Conditions Through Qigong Exercise: A Randomized Controlled Trial Completed NCT03591198
31 Proper Nutrition, Physical Exercise and Appropriate Weight in Individuals With Long Term Mental Illness Completed NCT00474227
32 Study of Arsha Vidya Chhatralaya Initiative on Health and Functioning of Disadvantaged Tribal Children Completed NCT03578159
33 Phospholipid Hypothesis of Depression: From Molecular Biology, Neuroimaging to Behaviour Completed NCT02615405
34 Efficacy of Dialectical Behavior Therapy in Patients With Borderline Personality Disorder: a Controlled Trial in Taiwan Completed NCT01952405
35 Addressing Motion and Confounds Issues in Resting fMRI- Application of Multi-echo EPI Scanning Completed NCT02720562
36 Leader's Eye Tracking Patterns Changes During High Fidelity Simulation Scenarios of Postpartum Hemorrhage Completed NCT04395963
37 Functional Rehabilitation of Older Patients With Schizophrenia Completed NCT00237796
38 Get Moving and Get Well: A Behavioral Activation Program for Veterans With SMI Completed NCT01884025
39 Community-Based Lifestyle Intervention for Primary and Secondary Prevention of Diabetes in Arab Women in East-Jerusalem, A Quasi-experimental Study. Completed NCT04143737
40 Hyperbaric Oxygenation in Treatment of Alcohol Dependence Syndrome Completed NCT03470168
41 The Effect of Transcranial Direct Current Stimulation on Human Brains: A Neuroimaging Study Completed NCT02421146
42 Effect of Psychoeducational Group Therapy Model for Bipolar Disorder Patients Completed NCT01152034
43 IVR-based Cognitive Behavior Therapy for Chronic Low Back Completed NCT01025752
44 Physician Training to Support Patient Self-Efficacy for Depression Care Behaviors Completed NCT01618552
45 The Clinical Efficacy of Acupuncture as an Adjunct to Methadone Treatment Services for Heroin Addicts: A Randomized Controlled Trial Completed NCT01512433
46 A Helping Hand (AHH) to Activate Patient-Centered Depression Care Among Low-Income Patients Completed NCT02147522
47 Development of an Internet-based Behavioral Pain Management Intervention Completed NCT01918189
48 Integrated Care & Patient Navigators for Latinos With Serious Mental Illness Completed NCT02469714
49 Wonders & Worries: A Clinical Trial of a Psychosocial Intervention for Children Who Have a Parent With Cancer Completed NCT02758639
50 The Effect of Cigarette Holders, Plastic Menthol Cigarettes, and Cognitive Behavioral Therapy for Smoking Reduction Among Schizophrenia Inpatients: A Comparative Study Completed NCT00302432

Search NIH Clinical Center for Physical Disorder

Genetic Tests for Physical Disorder

Anatomical Context for Physical Disorder

MalaCards organs/tissues related to Physical Disorder:

40
Brain, Testes, Heart, Breast, Eye, Thyroid, Cortex

Publications for Physical Disorder

Articles related to Physical Disorder:

(show top 50) (show all 3005)
# Title Authors PMID Year
1
Self-labeling as having a mental or physical illness: the effects of stigma and implications for help-seeking. 61
31641830 2020
2
Chronic Illness and Internalizing Symptomatology in a Transdiagnostic Clinical Sample of Youth. 61
32386417 2020
3
Perceived neighborhood and fall history among community-dwelling older adults living in a large Brazilian urban area: a multilevel approach. 61
32568556 2020
4
Microecological Relationships Between Area Income, Off-Premise Alcohol Outlet Density, Drinking Patterns, and Alcohol Use Disorders: The East Bay Neighborhoods Study. 61
32573798 2020
5
Poor Oral Health in Patients with Schizophrenia: a Meta-Analysis of Case-Control Studies. 61
32483766 2020
6
Perceptions, clinical characteristics, and other factors associated with prolonged and high daily dose of benzodiazepine use among patients with anxiety or depressive disorders. 61
32479319 2020
7
Elderly patients with no previous psychiatric history: suicidality and other factors relating to psychiatric acute admissions. 61
32552924 2020
8
Optimising Evidence-Based Psychological Treatment for the Mental Health Needs of Children with Epilepsy: Principles and Methods. 61
31965422 2020
9
Caring for patients with posttraumatic stress and substance use disorders during the COVID-19 pandemic. 61
32525388 2020
10
The relationship between age and suicidal thoughts and attempted suicide among prisoners. 61
32572829 2020
11
Somatic assessment of one hundred inpatients in a psychiatric crisis unit: A retrospective observational study. 61
31870494 2020
12
Risk factors for unplanned hospital admission in a specialist homeless general practice population: case-control study to investigate the relationship with tri-morbidity. 61
32424048 2020
13
Should euthanasia and assisted suicide for psychiatric disorders be permitted? A systematic review of reasons. 61
32482180 2020
14
Association of Early Treatment With Chronicity and Hazard of Hospitalization After New Adjustment Disorder. 61
31994408 2020
15
Prevalence of comorbid mental and physical illnesses and risks for self-harm and premature death among primary care patients diagnosed with fatigue syndromes. 61
31131782 2020
16
Spatial predictive properties of built environment characteristics assessed by drop-and-spin virtual neighborhood auditing. 61
32471502 2020
17
Medical home effects on enrollees with mental and physical illness. 61
32436679 2020
18
The Impact of Mental Illness Disclosure in Applying for Residency. 61
32415458 2020
19
Factors associated with quality of life for children affected by parental illness or substance abuse. 61
32383213 2020
20
Triggers and Clinical Presentations of Functional Neurological Disorders: Lessons from World War 1. 61
32454481 2020
21
[Medical Psychology and Medical Sociology in Transition - Review and Perspectives of the two Disciplines in Germany]. 61
31952094 2020
22
Learning and teaching approaches promoting resilience in student nurses: An integrated review of the literature. 61
32302957 2020
23
Development and initial validation of the Hopelessness Inventory for Later Life (HILL). 61
32426988 2020
24
Health Behaviors, Physical Health, and Health Care Utilization in Children With ADHD. 61
29806524 2020
25
The Foreclosure Crisis, Community Change, and the Cognitive Health of Older Adults. 61
32303760 2020
26
Measurement of Social Processes at the Neighborhood Level in Baltimore City. 61
32338382 2020
27
Community-Level Social Processes and Firearm Shooting Events: A Multilevel Analysis. 61
32107724 2020
28
Social capital and health status: longitudinal race and ethnicity differences in older adults from 2006 to 2014. 61
32086535 2020
29
Gender differences in metabolic syndrome risk factors among patients with serious mental illness. 61
31670454 2020
30
Physicians' knowledge and practices regarding screening adult patients for adverse childhood experiences: a survey. 61
32293444 2020
31
Association of ADHD symptoms, depression and suicidal behaviors with anxiety in Chinese medical college students. 61
32321462 2020
32
Childhood Adversities as Risk Factors and Persistence of Suicidal Behavior: A Descriptive Cross-Sectional Study. 61
32506095 2020
33
Antidepressant treatment for primary care patients with depressive symptoms: Data from the diamond longitudinal cohort study. 61
31957463 2020
34
[Mental Distress and Resilience in Severe Somatic Diseases: An Analysis of Dyadic Relations]. 61
32340059 2020
35
Developing a Framework of Integrated Competencies for Adaptive Expertise in Integrated Physical and Mental Health Care. 61
31482737 2020
36
Predictors of mortality in people with late-life depression: A retrospective cohort study. 61
32056946 2020
37
The experience of patients with cancer on narrative practice: A systematic review and meta-synthesis. 61
31944492 2020
38
Gender-specific risk for late-life suicide in rural China: a case-control psychological autopsy study. 61
32311006 2020
39
Psychopharmacology and ethnicity: A comparative study on Senegalese and Italian men. 61
31012797 2020
40
Self-regulation in childhood as a predictor of future outcomes: A meta-analytic review. 61
31904248 2020
41
Nutrition and immunology in mental health: Precision medicine and integrative approaches to address unmet clinical needs in psychiatric treatments. 61
31568824 2020
42
Is perceived neighbourhood physical disorder associated with muscle strength in middle aged and older men and women? Findings from the US health and retirement study. 61
31924624 2020
43
Mental health is the health of the whole body: How psychoneuroimmunology & health psychology can inform & improve treatment. 61
32171052 2020
44
The unique nature of public stigma toward non-medical prescription opioid use and dependence: a national study. 61
32219910 2020
45
Dyadic Psychosocial eHealth Interventions: Systematic Scoping Review. 61
32130143 2020
46
Self-reported health as a predictor of mortality: A cohort study of its relation to other health measurements and observation time. 61
32184429 2020
47
Quality of life and its association with current substance use, medication non-adherence and clinical factors of people with schizophrenia in Southwest Ethiopia: a hospital-based cross-sectional study. 61
32228624 2020
48
Attitudes Toward Euthanasia for Patients Who Suffer From Physical or Mental Illness. 61
29357754 2020
49
Variables associated with low, moderate and high emergency department use among patients with substance-related disorders. 61
31887605 2020
50
A community-based cross-sectional study of sleep quality among internal migrant workers in the service industry. 61
31884329 2020

Variations for Physical Disorder

Expression for Physical Disorder

Search GEO for disease gene expression data for Physical Disorder.

Pathways for Physical Disorder

Pathways related to Physical Disorder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.28 SHH MSX1 FGF8
2 9.91 SHH FGF8

GO Terms for Physical Disorder

Biological processes related to Physical Disorder according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 roof of mouth development GO:0060021 9.63 SHH MSX1 IRF6
2 neurogenesis GO:0022008 9.61 WDR62 ERCC6 CDK5RAP2
3 epithelial to mesenchymal transition involved in endocardial cushion formation GO:0003198 9.51 MSX1 FGF8
4 branching involved in salivary gland morphogenesis GO:0060445 9.49 SHH FGF8
5 microtubule organizing center organization GO:0031023 9.48 PAFAH1B1 CDK5RAP2
6 odontogenesis GO:0042476 9.43 SHH MSX1 FGF8
7 maintenance of centrosome location GO:0051661 9.4 PAFAH1B1 ASPM
8 mesenchymal cell proliferation GO:0010463 9.37 SHH MSX1
9 establishment of mitotic spindle orientation GO:0000132 9.33 PAFAH1B1 MCPH1 CDK5RAP2
10 regulation of odontogenesis GO:0042481 9.32 SHH MSX1
11 embryonic hindlimb morphogenesis GO:0035116 9.13 SHH MSX1 FGF8
12 cerebral cortex development GO:0021987 8.92 WDR62 PAFAH1B1 MCPH1 ASPM

Sources for Physical Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....